Spark Gene Eye Therapy Pioneer Pleads: All Therapies Are Not Created Equal
This article was originally published in The Pink Sheet Daily
On the rebound from a brief stock beating after the high profile failure of similar yet different therapies, Spark Therapeutics distances its gene therapy for genetic eye disorders and assures investors that all’s well in Phase III.
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.